RxDoctor Payments Data

Kenny Smith, MD

Internal Medicine · Gadsden, ALNPI 1295736460

Payments from drug & device makers

$1,368in general payments, 2019–2025

Across 83 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$296
  • Teva Pharmaceuticals USA, Inc.$159
  • Bayer$108
  • Lundbeck LLC$105
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$88
  • Otsuka America Pharmaceutical, Inc.$75
  • plus $538 from 14 others

What the payments were for

  • Food & beverage$1,368100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,368 in reported general payments places this provider in the 65th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$55,106
Medicare patients
133
Services billed
583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban667$207,234
IngrezzaValbenazine Tosylate15$75,943
MounjaroTirzepatide58$59,035
CreonLipase/Protease/Amylase13$48,498
Austedo XrDeutetrabenazine21$48,485
XareltoRivaroxaban104$40,245
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,349$38,542
JardianceEmpagliflozin93$32,083
JanuviaSitagliptin Phosphate78$31,699
Lagevrio (Eua)Molnupiravir23$23,019
AptiomEslicarbazepine Acetate24$20,864
LinzessLinaclotide38$20,640
MyrbetriqMirabegron84$20,458
Fentanyl191$20,165
MovantikNaloxegol Oxalate46$19,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lyrica$52$226,194690 claims
AbbVieCreon, Linzess, Namzaric$18$81,27791 claims
Neurocrine Biosciences, Inc.Ingrezza$23$75,94315 claims
Lilly USA, LLCMounjaro$20$59,03558 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$159$48,48521 claims
Johnson & JohnsonXarelto$31$40,245104 claims
Sunovion Pharmaceuticals Inc.Aptiom$296$20,86424 claims
Redhill Biopharma Inc.Movantik$23$19,81446 claims
AstraZenecaFarxiga$63$16,91424 claims
NovartisEntresto$71$7,49021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Gadsden

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →